Based on the Royalty Pharma Plc stock forecast from 4 analysts, the average analyst target price for Royalty Pharma Plc is USD 45.00 over the next 12 months. Royalty Pharma Plc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Royalty Pharma Plc is Neutral, which is based on 8 positive signals and 8 negative signals. At the last closing, Royalty Pharma Plc’s stock price was USD 33.42. Royalty Pharma Plc’s stock price has changed by +3.28% over the past week, +11.10% over the past month and +7.70% over the last year.
No recent analyst target price found for Royalty Pharma Plc
No recent average analyst rating found for Royalty Pharma Plc
Company Overview Royalty Pharma Plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York. Read Less
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that add...Read More
Frequently Asked Questions About Royalty Pharma Plc (RPRX) Stock
Based on ratings from 4 analysts Royalty Pharma Plc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 5 buy, sell and hold ratings.
RPRX stock's dividend yield is 2.72%.
Our analysis grades RPRX stock's dividend yield at F. This means that RPRX stock's dividend yield is above 33% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this RPRX may be a poor dividend stock for its sector.
Based on targets from 4 analysts, the average taret price for RPRX is USD 45.00 over the next 12 months. The maximum analyst target price is USD 51 while the minimum anlayst target price is USD 40.
RPRX stock's Price/Earning ratio is 16.94.
Our analysis grades RPRX stock's Price / Earning ratio at F. This means that RPRX stock's Price/Earning ratio is above 67% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this RPRX may be a overvalued for its sector.
The last closing price of RPRX's stock was USD 33.42.
The most recent market capitalization for RPRX is USD 18.65B.
Based on targets from 4 analysts, the average taret price for RPRX is projected at USD 45.00 over the next 12 months.
This means that RPRX's stock price may go up by +34.65% over the next 12 months.
We can't find any ETFs which contains Royalty Pharma Plc's stock.
As per our most recent records Royalty Pharma Plc has 0 Employees.
Royalty Pharma Plc's registered address is 110 East 59th Street, New York, NY, United States, 10022.
You can get more information about it from Royalty Pharma Plc's website at https://www.royaltypharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Royalty Pharma Plc (RPRX) Stock
Based on ratings from 4 analysts Royalty Pharma Plc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 5 buy, sell and hold ratings.
RPRX stock's dividend yield is 2.72%.
Our analysis grades RPRX stock's dividend yield at F. This means that RPRX stock's dividend yield is above 33% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this RPRX may be a poor dividend stock for its sector.
Based on targets from 4 analysts, the average taret price for RPRX is USD 45.00 over the next 12 months. The maximum analyst target price is USD 51 while the minimum anlayst target price is USD 40.
RPRX stock's Price/Earning ratio is 16.94.
Our analysis grades RPRX stock's Price / Earning ratio at F. This means that RPRX stock's Price/Earning ratio is above 67% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this RPRX may be a overvalued for its sector.
The last closing price of RPRX's stock was USD 33.42.
The most recent market capitalization for RPRX is USD 18.65B.
Based on targets from 4 analysts, the average taret price for RPRX is projected at USD 45.00 over the next 12 months.
This means that RPRX's stock price may go up by +34.65% over the next 12 months.
We can't find any ETFs which contains Royalty Pharma Plc's stock.
As per our most recent records Royalty Pharma Plc has 0 Employees.
Royalty Pharma Plc's registered address is 110 East 59th Street, New York, NY, United States, 10022.
You can get more information about it from Royalty Pharma Plc's website at https://www.royaltypharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for RPRX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
